SI1545587T1 - Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede - Google Patents

Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede

Info

Publication number
SI1545587T1
SI1545587T1 SI200331990T SI200331990T SI1545587T1 SI 1545587 T1 SI1545587 T1 SI 1545587T1 SI 200331990 T SI200331990 T SI 200331990T SI 200331990 T SI200331990 T SI 200331990T SI 1545587 T1 SI1545587 T1 SI 1545587T1
Authority
SI
Slovenia
Prior art keywords
methods
diabetic ulcer
ulcer treatment
lactoferrin compositions
lactoferrin
Prior art date
Application number
SI200331990T
Other languages
English (en)
Slovenian (sl)
Inventor
Jose Engelmayer
Atul Varadhachary
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Publication of SI1545587T1 publication Critical patent/SI1545587T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
SI200331990T 2002-09-16 2003-09-16 Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede SI1545587T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41098102P 2002-09-16 2002-09-16
EP03752398A EP1545587B1 (en) 2002-09-16 2003-09-16 Lactoferrin compositions and methods of diabetic ulcer treatment
PCT/US2003/029069 WO2004024180A1 (en) 2002-09-16 2003-09-16 Lactoferrin compositions and methods of wound treatment

Publications (1)

Publication Number Publication Date
SI1545587T1 true SI1545587T1 (sl) 2011-06-30

Family

ID=31994228

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200332199T SI2298338T1 (sl) 2002-09-16 2003-09-16 Laktoferinski sestavki in postopki za zdravljenjekožnih ran
SI200331990T SI1545587T1 (sl) 2002-09-16 2003-09-16 Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200332199T SI2298338T1 (sl) 2002-09-16 2003-09-16 Laktoferinski sestavki in postopki za zdravljenjekožnih ran

Country Status (12)

Country Link
US (3) US7524814B2 (enExample)
EP (2) EP1545587B1 (enExample)
JP (1) JP4516844B2 (enExample)
CN (1) CN1694720A (enExample)
AT (1) ATE497778T1 (enExample)
AU (2) AU2003270690B2 (enExample)
CA (1) CA2499014A1 (enExample)
DE (1) DE60335997D1 (enExample)
DK (2) DK2298338T3 (enExample)
ES (1) ES2358645T3 (enExample)
SI (2) SI2298338T1 (enExample)
WO (1) WO2004024180A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
AU2003273182B8 (en) 2002-05-10 2009-05-07 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) * 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DE60335997D1 (de) 2002-09-16 2011-03-24 Agennix Inc Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
US20040152624A1 (en) * 2002-12-06 2004-08-05 Atul Varadhachary Oral lactoferrin in the treatment of sepsis
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
CN101039696B (zh) * 2004-08-20 2011-08-17 史密丝克莱恩比彻姆公司 给药人il-18治疗创伤的方法
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
US8263105B2 (en) * 2004-12-01 2012-09-11 Tyco Healthcare Group Lp Biomaterial drug delivery and surface modification compositions
ITRM20040638A1 (it) 2004-12-24 2005-03-24 Advance Holdings Ltd Gel piastrinico semisintetico e metodo per la sua preparazione.
US20060240116A1 (en) * 2005-04-22 2006-10-26 David Jolley Bioactive factors in wound healing topical compositions and methods
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007022537A2 (en) * 2005-08-19 2007-02-22 Agennix Incorporated Use of lactoferrin as a chemokine and a chemotactic modulator
US20070059300A1 (en) * 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
US20070116750A1 (en) * 2005-11-18 2007-05-24 Randall Wolcott Compositions for disrupting and inhibiting reconstitution of wound biofilm
US20070179084A1 (en) * 2006-01-30 2007-08-02 Nation Chiao Tung University Process for reducing the concentration of blood glucose in a diabetic patient
EP1815877B1 (en) * 2006-02-02 2009-11-25 Euro-Celtique S.A. Hydrogel for the treatment of wounds
WO2007100555A2 (en) * 2006-02-21 2007-09-07 Ventria Bioscience Compositions containing lactoferrin, and methods of using same to promote growth of skin cells
CN101528253A (zh) * 2006-07-03 2009-09-09 让-保罗·佩罗丹 抗菌剂组合物及其用途
GB0616580D0 (en) * 2006-08-21 2006-09-27 Novathera Ltd Composite material
CA2663417A1 (en) * 2006-09-13 2008-03-20 Southeastern Medical Technologies, Llc Methods and compositions for sealing and adhering biological tissues and medical uses thereof
US10143694B2 (en) * 2006-10-27 2018-12-04 Matthew H. Kopacki Advanced formulations and therapies for treating hard-to-heal wounds
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
WO2009123720A2 (en) * 2008-04-01 2009-10-08 Southeastern Medical Technologies, Llc Methods and compositions for medical articles produced from proteinaceous compounds
EP2141242A1 (en) * 2008-07-04 2010-01-06 Universität des Saarlandes Synthetic pathway enzymes for the production of Argyrins
US8614189B2 (en) * 2008-09-24 2013-12-24 University Of Connecticut Carbon nanotube composite scaffolds for bone tissue engineering
US20110015587A1 (en) * 2009-07-14 2011-01-20 Tumey David M Irrigation Device and Method Using Same
JP2011020973A (ja) * 2009-07-17 2011-02-03 Nrl Pharma Inc 難治性の皮膚潰瘍治療用の医薬組成物、及び、皮膚潰瘍予防用化粧料
WO2011066175A1 (en) * 2009-11-25 2011-06-03 Nestec S.A. Nutritional compositions including a high protein component and exogenous nucleotides
AU2011251991B2 (en) 2010-05-10 2014-05-22 University Of Connecticut Lactoferrin -based biomaterials for tissue regeneration and drug delivery
WO2012000054A1 (en) * 2010-07-01 2012-01-05 Brien Holden Vision Institute Lactoferrin sequences, compositions and methods of corneal wound treatment
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
US20120171231A1 (en) * 2010-12-29 2012-07-05 Anja Wittke Use of nutritional compositions including lactoferrin in stimulating immune cells
EP2668956A4 (en) * 2011-01-26 2015-11-11 Megmilk Snow Brand Co Ltd MEANS FOR IMPROVED SENSUAL ASSESSMENT
CA2826192A1 (en) 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
US10172984B2 (en) * 2011-08-31 2019-01-08 Kci Licensing, Inc. Reduced-pressure treatment and debridement systems and methods
WO2014078581A1 (en) * 2012-11-14 2014-05-22 Smith & Nephew, Inc. Stable thermolysin hydrogel
US11452698B2 (en) 2013-03-15 2022-09-27 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
JP6275955B2 (ja) * 2013-04-25 2018-02-07 松尾 敏郎 塩化マグネシウムを摂取する人を除いた生物の細胞の活性化方法
CZ308554B6 (cs) * 2013-10-21 2020-11-25 Univerzita Tomáše Bati ve Zlíně Hydrogelová kosmetická nebo farmaceutická kompozice s účinnějším působením v ní obsažených biologicky aktivních látek z hlediska antimikrobiálních účinků
US20170304409A1 (en) 2014-09-24 2017-10-26 ISTITUTO PROFILATTICO E FARMACEUTICO CANDIOLI & C. SPA in abbreviated form CANDIOLI FARMACEUTICI Compositions useful for the prevention and/or treatment of infections and inflammations
RU2658707C1 (ru) * 2016-12-28 2018-06-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ восстановления кожного покрова
US20200024329A1 (en) 2018-07-17 2020-01-23 Bradley G. Thompson Methods for regulating endogenous production of lactoferrin and sub-peptides thereof
JP7140431B2 (ja) * 2018-07-31 2022-09-21 レモネックス インコーポレイテッド 傷治療用の医薬組成物
EP3893920B1 (en) * 2018-12-11 2024-09-18 Universitá Degli Studi Di Salerno Composition for the treatment of skin lesions
CN110075054A (zh) * 2019-06-06 2019-08-02 山东天源人乳库科技发展有限公司 一种来源于人乳的人源性生长因子修复制剂及其制备方法
BE1027357B1 (nl) * 2019-06-12 2021-01-18 Vanlommel Maria Kristel Voedingssupplement voor versnelde genezing
CN110680949B (zh) * 2019-10-18 2021-06-29 中山大学 一种基于母乳的创伤敷料的制备方法和应用
UY39909A (es) * 2021-08-23 2023-03-31 Lactea Therapeutics Llc Composiciones de lactoferrina y métodos de uso
CN113576938B (zh) * 2021-08-26 2022-07-08 广东丸美生物技术股份有限公司 一种口腔护理组合物及其应用
US20240165297A1 (en) * 2022-08-19 2024-05-23 Philip Neil MacPherson Hydrogel delivery matrix
CN116421775A (zh) * 2023-04-21 2023-07-14 青岛优瑞达生物科技有限公司 一种乳铁蛋白凝胶敷料、制备方法和应用
CN116251224B (zh) * 2023-05-16 2023-09-12 江苏正大天创生物工程有限公司 一种乳铁蛋白凝胶敷料及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4788488A (en) * 1986-10-14 1988-11-29 Drexelbrook Controls, Inc. Continuous condition sensing system
US4783488A (en) * 1987-01-31 1988-11-08 Bausch & Lomb Incorporated Contact lens wetting solution
US4977137B1 (en) 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5705485A (en) 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US6100054A (en) 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5766939A (en) 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571691A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
IL94183A (en) 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5571697A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5849881A (en) 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US5198419A (en) 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
AU655161B2 (en) * 1990-01-12 1994-12-08 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of enhancing wound healing and tissue repair
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US6066469A (en) 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
GB2248842A (en) * 1990-10-16 1992-04-22 American Cyanamid Co Film-forming polymer compositions
DK0579830T3 (da) * 1990-11-13 1997-08-18 Santen Pharmaceutical Co Ltd Terapeutisk middel til hornhindebeskadigelse
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
CA2126438C (en) 1991-12-24 2003-12-02 Jac A. Nickoloff Site-directed mutagenesis of dna
DK0559425T3 (da) * 1992-03-02 1999-08-30 Japan Immuno Inc Anvendelse af proteiner tilhørende transferrin/lactoferrinfamilien til stimulering af immunsystemet
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
GB2272375B (en) * 1992-04-10 1996-02-14 Vnii Med Polimerov Pharmaceutical composition
ZA932568B (en) 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
JPH07196529A (ja) * 1993-12-29 1995-08-01 Morinaga Milk Ind Co Ltd 創傷治癒剤、化粧料および養毛剤
FI963197A7 (fi) 1994-02-16 1996-08-15 Pharming Intellectual Property Bv Laktoferriinin eristäminen maidosta
JP3746081B2 (ja) 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
US5827874A (en) 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
US6111081A (en) 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
GB2321191B (en) 1997-01-17 2000-09-27 Johnson & Johnson Medical Peptides for use in wound treatment
US6333311B1 (en) 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof
ATE297755T1 (de) 1997-04-10 2005-07-15 Agennix Inc Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
JP3856908B2 (ja) * 1997-06-06 2006-12-13 田辺製薬株式会社 褥瘡及び／又は創傷治療剤
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
EP1404412B1 (en) 2001-06-13 2012-03-21 The University of Sydney Protein C for wound healing
AU2003273182B8 (en) 2002-05-10 2009-05-07 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DE60335997D1 (de) * 2002-09-16 2011-03-24 Agennix Inc Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
WO2004050037A2 (en) 2002-12-04 2004-06-17 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
US20040152624A1 (en) 2002-12-06 2004-08-05 Atul Varadhachary Oral lactoferrin in the treatment of sepsis
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2003293500A1 (en) * 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
WO2004103285A2 (en) 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrin in the treatment of diabetes mellitus
US8105615B2 (en) 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects

Also Published As

Publication number Publication date
EP1545587A1 (en) 2005-06-29
EP1545587A4 (en) 2009-06-17
EP2298338A1 (en) 2011-03-23
US8247373B2 (en) 2012-08-21
DK2298338T3 (da) 2012-09-24
DE60335997D1 (de) 2011-03-24
US20090253627A1 (en) 2009-10-08
AU2009225309B2 (en) 2012-06-14
AU2003270690B2 (en) 2009-07-30
WO2004024180A1 (en) 2004-03-25
US20040142037A1 (en) 2004-07-22
ES2358645T3 (es) 2011-05-12
AU2009225309A1 (en) 2009-11-05
JP4516844B2 (ja) 2010-08-04
EP1545587B1 (en) 2011-02-09
CN1694720A (zh) 2005-11-09
US20120010150A1 (en) 2012-01-12
SI2298338T1 (sl) 2012-11-30
DK1545587T3 (da) 2011-05-09
CA2499014A1 (en) 2004-03-25
US7524814B2 (en) 2009-04-28
EP2298338B1 (en) 2012-08-22
AU2003270690A1 (en) 2004-04-30
US8030272B2 (en) 2011-10-04
JP2006503044A (ja) 2006-01-26
ATE497778T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
SI1545587T1 (sl) Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede
DE60036169D1 (de) Methoden zur Behandlung der Hautpigmentierung
PL1615952T3 (pl) Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2
SI1434791T1 (sl) Posebni vezni agensi humanega angiopoietina-2
AU2003274941A1 (en) A method of treating human skin and a skin care composition for use in such a method
EP1430873A4 (en) CAPILLARY TREATMENT AGENT COMPOSITION AND PROCESS FOR PREPARING THE SAME
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
MXPA02007059A (es) Composicion de autobronceado que contiene un ester n-acilado de aminoacido y un agente de autobronceado.
CA2070685A1 (en) Method for treating painful, inflammatory or allergic disorders
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
EP1549324A4 (en) COMPOSITION AND METHOD FOR BRIGHTENING SKIN
IL161073A0 (en) Composition and method for treating diabetes
TWI348912B (en) Method and composition for treating skin wounds with epidermal growth factor
EP1648399A4 (en) METHOD AND TOPIC COMPOSITION FOR TREATING SKIN HYPERPIGMENTATION
EP1425027A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF WOUNDS AND BURNS
AU2003262840A1 (en) Composition and method for treating skin
MXPA05009110A (es) Composiciones coloreadas particuladas y su uso en productos de cuidado personal.
TW200744660A (en) Oral composition containing morin
GB2399500B (en) Composition and method for treatment of wounds
AU2003290970A8 (en) Compositions and method for treating affective, painful or allergic disorders
AU2003291461A1 (en) Compositions for diabetes treatment and prophylaxis
DE60210313D1 (de) Verwendung von dattelkern-extrakt zur minderung der anzeichen der hautalterung
GB0409694D0 (en) A composition for use in the treatment or prophylaxis of a skin condition in a subject
IL164536A0 (en) The use of hydroxypyridone-derivatives in wound healing
AU2003252185A8 (en) Topical composition for the treatment of scar tissue